Back to Authors

Rokitka, Denise A.

0009-0005-5992-6531

Mayo Clinic

Roswell Park Comprehensive Cancer Center

Citations 2

Wilms Tumor, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Benedetti, Daniel J. , Brown, Brandon , Cook, Shelly, Desai, Ami V. , Fair, Douglas , Hiniker, Susan M. , Jasty‐Rao, Rama, Just, Marissa, Kieran, Kathleen , Lin, Chi , MacEwan, Iain, Martínez-Agosto, Julián A. , Mullen, Elizabeth A. , Murphy, Erin S. , Ranalli, Mark , Rhee, Daniel S. , Wickiser, Jonathan E., Yoon, Janet, Zapala, Matthew A. , Sliker, Bailee , Horst, Kelly , Balis, Frank M. , Green, Daniel M. , Armstrong, Amy J. , Aye, Jamie M. , Brown, Brandon Douglas , Brown, Erin G. , Dhillon, Jasreman , Geynisman, Daniel M. , Horst, Kelly K. , Pinto, Navin , Rokitka, Denise A. , Walz, Amy L. , Montgomery, Sarah E.

Journal of the National Comprehensive Cancer Network | August 5, 2025 | Volume: 23 | Issue: 8 | Pages: 319-342

10.6004/jnccn.2025.0037 Get It

The NCCN Clinical Practice Guidelines (NCCN Guidelines) for Wilms Tumor (WT; nephroblastoma) cover strategies for the screening, diagnosis, and treatment of WT, which is the most frequent primary kidney tumor in children. WT can generally be separated into 2 histology types: favorable histology WT and anaplastic WT. Five-year survival is high for children with favorable histology WT who receive appropriate treatment; however, survival rates are much lower for patients who present with higher stage diffuse anaplastic WT. Treatment of WT can range from surgery alone to surgery plus intensive chemotherapy and radiation depending on whether the tumor is unilateral or bilateral, histology, and local stage. The goal of therapy is to maximize cure while minimizing long-term toxicities. The content featured in this issue covers the NCCN panel’s recommendations for overall management of both favorable histology WT and anaplastic WT.
Wilms Tumor (Nephroblastoma), Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Anderson, Clarke, Cook, Shelly, Gow, Kenneth W. , Hiniker, Susan M. , Jasty‐Rao, Rama, Lin, Chi , Lovvorn, Harold N. , MacEwan, Iain, Martínez-Agosto, Julián A. , Mullen, Elizabeth A. , Murphy, Erin S. , Ranalli, Mark , Rhee, Daniel S. , Tracy, Elisabeth T. , Vern-Gross, T.Z., Walsh, Michael F. , Wickiser, Jonathan E., Zapala, Matthew A. , Berardi, Ryan A., Hughes, Miranda, Vern-Gross, Tamara, Tracy, Elisabeth T , Balis, Frank M. , Green, Daniel M. , Dhillon, Jasreman , Rokitka, Denise A. , Walz, Amy L.

Journal of the National Comprehensive Cancer Network | August 20, 2021 | Volume: 19 | Issue: 8 | Pages: 945-977

10.6004/jnccn.2021.0037 Get It

The NCCN Guidelines for Wilms Tumor focus on the screening, diagnosis, staging, treatment, and management of Wilms tumor (WT, also known as nephroblastoma). WT is the most common primary renal tumor in children. Five-year survival is more than 90% for children with all stages of favorable histology WT who receive appropriate treatment. All patients with WT should be managed by a multidisciplinary team with experience in managing renal tumors; consulting a pediatric oncologist is strongly encouraged. Treatment of WT includes surgery, neoadjuvant or adjuvant chemotherapy, and radiation therapy (RT) if needed. Careful use of available therapies is necessary to maximize cure and minimize long-term toxicities. This article discusses the NCCN Guidelines recommendations for favorable histology WT.